risperidone has been researched along with Hyperprolactinemia in 139 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Hyperprolactinemia: Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Between February 2009 and November 2013, medically healthy, 5- to 17-year-old boys were enrolled in a 36-week double-blind, placebo-controlled study, examining the skeletal effects of supplementation with 1250 mg calcium carbonate and 400 IU of vitamin D3 in risperidone-induced hyperprolactinemia." | 9.27 | Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study. ( Calarge, CA; Mills, JA; Schlechte, JA; Ziegler, EE, 2018) |
| "This study aimed to investigate prolactin related symptoms (PRS) in individuals with schizophrenia during risperidone maintenance treatment for one year, as well as to identify the risk factors for PRS." | 9.22 | Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia. ( Bo, Q; Dong, F; Li, X; Ma, X; Wang, C; Wang, Z, 2016) |
| "The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia." | 9.20 | Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial. ( Ai, X; Ding, M; Ding, S; Gu, X; Huang, G; Li, X; Lv, L; Pang, L; Song, X; Zhao, J, 2015) |
| "Antipsychotics, such as aripiprazole and risperidone, are often used to treat individuals with schizophrenia." | 9.19 | Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. ( Gu, N; Kane, JM; Li, H; Luo, J; Wang, C; Wang, X; Xie, S; Xu, X; Yu, W, 2014) |
| "We sought to assess the effect of the addition of a fixed dose of 5 mg daily of aripiprazole on hyperprolactinemia induced by risperidone long-acting injectable (RLAI) treatment in patients with chronic psychoses and the adverse events related to the addition of aripiprazole and its impact on the disease." | 9.17 | Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. ( Bonete Llácer, JM; García Escudero, MA; Martínez Pastor, CJ; Ziadi Trives, M, 2013) |
| "In this 6-week, multicenter, randomized, rater single-blind study, a total of 119 patients with schizophrenia were randomly assigned to quetiapine (n = 60, 750 mg/day) or risperidone (n = 59, 4 mg/day)." | 9.16 | Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study. ( Li, H; Li, Y; Liu, Y; Qian, M; Yan, X; Yue, Y, 2012) |
| "Hyperprolactinemia, an adverse effect associated with the use of typical antipsychotics and the atypical antipsychotic risperidone, has both acute and chronic clinical consequences." | 9.14 | Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. ( Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R, 2009) |
| "The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design." | 9.14 | Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. ( Bahk, WM; Cho, HS; Jeon, YW; Jon, DI; Jung, HY; Kim, CH; Kim, HC; Kim, SH; Kim, YH; Kim, YK; Kwon, JS; Lee, SH; Lee, SY; Yang, J; Yi, JS; Yoon, BH, 2010) |
| "To compare the efficacy and tolerability of quetiapine and risperidone in the treatment of schizophrenia." | 9.12 | Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. ( Hamer, RM; Lieberman, JA; Sweitzer, DE; Zhong, KX, 2006) |
| "2 years) inpatients with depressive and anxiety disorders who were treated with risperidone (median doses per day 1." | 9.12 | Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia. ( Bares, M; Horacek, J; Kopecek, M; Mohr, P, 2006) |
| " Thus, we compared ziprasidone and risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder." | 9.11 | Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. ( Addington, DE; Benattia, I; Dineen, M; Pantelis, C; Romano, SJ, 2004) |
| "The prevalence of hyperprolactinemia during treatment with conventional antipsychotic drugs or risperidone is under-recognized and requires further investigation." | 9.10 | Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. ( Gilmore, JA; Halbreich, UM; Kinon, BJ; Liu, H, 2003) |
| "This study was conducted to prospectively examine the effect of switching from risperidone to olanzapine on female schizophrenia patients who experienced menstrual disturbances, galactorrhea, and/or sexual dysfunction." | 9.10 | Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. ( Bahk, WM; Chae, JH; Dickson, RA; Jun, TY; Kim, DJ; Kim, KS; Pae, CU, 2002) |
| "Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children." | 8.81 | Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. ( Biederman, J; Cohen, LG, 2001) |
| "Risperidone and amisulpride caused hyperprolactinemia and macroprolactinemia; thus, detection of MPRL in the clinical setting should be performed as this phenomenon appears early in treatment (the second week) and continues, that can avoid unnecessary examination and treatment for asymptomatic patients with macroprolactinemia." | 8.12 | Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride. ( Haiying, J; Haizhi, C; Jianhua, L; Jianjun, L; Jing, L; Lilei, L; Xiaocong, F; Zhenhua, W, 2022) |
| "We found very common hyperprolactinemia and hypoprolactinemia in the risperidone or paliperidone group and aripiprazole group, respectively." | 8.02 | Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. ( Shimoda, K; Shinozaki, M; Sugawara, N; Tasaki, M; Yasui-Furukori, N; Yokoyama, S, 2021) |
| "The aim of this study was to explore the effectiveness and tolerability of long-acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients while comparing the results with the oral antipsychotic risperidone." | 7.91 | Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients. ( Gačo, N; Graovac, M; Kaštelan, A; Petrić, D; Rački, V, 2019) |
| "The aim of this study was to investigate the association of drug-metabolizing enzyme and transporter (DMET) polymorphisms with the risperidone-induced prolactin response using an overlapping gene model between serum prolactin level and hyperprolactinemia in autism spectrum disorder (ASD) patients." | 7.88 | UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder. ( Chamnanphon, M; Hongkaew, Y; Limsila, P; Medhasi, S; Ngamsamut, N; Pasomsub, E; Puangpetch, A; Sukasem, C; Suthisisang, C; Vanwong, N; Wilffert, B, 2018) |
| "This study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in Han Chinese women with schizophrenia." | 7.83 | Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. ( Guo, Q; Li, C; Ouyang, Q; Qiao, Y; Shen, W; Sheng, J; Wen, H; Yang, F; Zhu, S, 2016) |
| "Hyperprolactinemia is commonly seen in patients with schizophrenia on risperidone." | 7.83 | Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia. ( Chandrasekaran, A; Charan, A; Rajkumar, RP; Shewade, DG, 2016) |
| "In children and adolescents treated with risperidone, hyperprolactinemia is a frequent complication that may have clinical repercussions." | 7.81 | Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects. ( Celeri, EH; Dalgalarrondo, P; de Mello, MP; Della Torre, OH; dos Santos Júnior, A; Ferreira Neto, AP; Fontana, TS; Guerra Júnior, G; Henriques, TB; Paes, LA; Sewaybricker, LE, 2015) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 7.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| "Hyperprolactinemia is a common side effect in young males treated over the long term with risperidone." | 7.78 | Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. ( Boot, AM; Buitelaar, JK; Roke, Y; Tenback, D; van Harten, PN, 2012) |
| " Inter-individual variability in hyperprolactinemia induced antipsychotics particularly risperidone can be explained by smoking status to some extent." | 7.77 | The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. ( Furukori, H; Kaneko, S; Nakagami, T; Ohta, C; Saito, M; Tsuchimine, S; Yasui-Furukori, N; Yoshizawa, K, 2011) |
| "Hyperprolactinemia is associated with typical antipsychotic agents and atypical antipsychotics such as risperidone and amisulpride." | 7.76 | Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. ( Chen, CK; Hsiao, CC; Huang, YS; Ree, SC, 2010) |
| "Hyperprolactinemia is a frequent consequence of treatment with risperidone." | 7.76 | Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. ( Fujii, A; Furukori, H; Kaneko, S; Sugawara, N; Yasui-Furukori, N, 2010) |
| "To investigate the association between hyperprolactinemia and variants of the dopamine D2 receptor (DRD2) gene in children and adolescents in long-term treatment with risperidone." | 7.75 | Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. ( Acion, L; Calarge, CA; Ellingrod, VL; Miller, DD; Moline, J; Schlechte, JA; Tansey, MJ, 2009) |
| "Hyperprolactinemia can be a complication of conventional neurolepics as well as risperidone." | 7.75 | Attenuation of risperidone-induced hyperprolactinemia with the addition of aripiprazole. ( Capote, HA; Gengo, FM; Rainka, MM; Ross, CA, 2009) |
| "Studies performed in adult patients unambiguously demonstrate a marked effect of risperidone on prolactin blood levels, with possible clinical effects related to hyperprolactinemia, such as gynecomastia and galactorrhea." | 7.73 | Risperidone-induced symptomatic hyperprolactinaemia in adolescents. ( Eap, CB; Holzer, L, 2006) |
| "Prolactin levels returned to normal, and clinical symptoms of hyperprolactinemia resolved in all 3 patients after 2 weeks of tapering and discontinuation of risperidone." | 7.73 | Risperidone-induced hyperprolactinemia in adolescents: A case series. ( Madhusoodanan, S; Moise, D, 2006) |
| "To report a case of risperidone-induced hyperprolactinemia that was successfully managed with quetiapine." | 7.72 | Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine. ( Kunwar, AR; Megna, JL, 2003) |
| "Nineteen male and female DSM-IV-defined schizophrenic patients who were clinical responders to risperidone but were suffering from symptomatic hyperprolactinemia were treated with cabergoline, 0." | 7.72 | Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. ( Angelone, SM; Cavallaro, R; Cocchi, F; Lattuada, E; Smeraldi, E, 2004) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 7.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| " Overall, 63 (94%) patients experienced at least one treatment-emergent adverse event (TEAE)." | 6.87 | A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. ( Anta, L; Ayani, I; Gutierro, I; Litman, RE; Llaudó, J; Martínez, J, 2018) |
| " However, the ideal dosing regimen for this purpose is unknown." | 6.80 | Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. ( Bian, QT; Chen, JX; Correll, C; Liu, YH; Soares, JC; Su, YA; Wang, SL; Wei, LH; Yang, FD; Zhang, RZ; Zhang, XY, 2015) |
| "Hyperprolactinemia is an important but neglected adverse effect of antipsychotic medication." | 6.73 | Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. ( Chen, CH; Lu, ML; Shen, WW, 2008) |
| "Hyperprolactinemia is a common adverse effect that occurs as a result of antipsychotic therapies, which often results in discontinuation." | 6.73 | A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. ( Feng, XJ; Liu, RM; Sze, CW; Tan, QR; Tong, Y; Wang, CY; Yuan, HN; Zhang, JZ; Zhang, YB; Zhang, ZJ, 2008) |
| "Risperidone is known to increase prolactin secretion in treating mental illness patients." | 5.46 | The central mechanism of risperidone-induced hyperprolactinemia. ( Huang, XF; Li, LY; Lin, S; Shi, YC; Song, ZY; Sun, WW; Yang, HQ, 2017) |
| "These results suggest that hyperprolactinaemia may develop during risperidone treatment." | 5.43 | 9-Hydroxyrisperidone-Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder. ( Chamkrachangpada, B; Hongkaew, Y; Limsila, P; Ngamsamut, N; Puangpetch, A; Srisawasdi, P; Sukasem, C; Tan-Khum, T; Vanwong, N, 2016) |
| "Medicamentous hyperprolactinaemia is a well known side effect of risperidone." | 5.36 | Hyperprolactinaemia - a risperidone side-effect. ( Dadić-Hero, E; Grahovac, T; Medved, P; Pavesić-Radonja, A; Ruzić, K, 2010) |
| "Risperidone is a novel antipsychotic agent that blocks both dopaminergic and serotonergic receptors." | 5.31 | Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. ( Tollin, SR, 2000) |
| "Between February 2009 and November 2013, medically healthy, 5- to 17-year-old boys were enrolled in a 36-week double-blind, placebo-controlled study, examining the skeletal effects of supplementation with 1250 mg calcium carbonate and 400 IU of vitamin D3 in risperidone-induced hyperprolactinemia." | 5.27 | Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study. ( Calarge, CA; Mills, JA; Schlechte, JA; Ziegler, EE, 2018) |
| "This study aimed to investigate prolactin related symptoms (PRS) in individuals with schizophrenia during risperidone maintenance treatment for one year, as well as to identify the risk factors for PRS." | 5.22 | Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia. ( Bo, Q; Dong, F; Li, X; Ma, X; Wang, C; Wang, Z, 2016) |
| "The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia." | 5.20 | Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial. ( Ai, X; Ding, M; Ding, S; Gu, X; Huang, G; Li, X; Lv, L; Pang, L; Song, X; Zhao, J, 2015) |
| "Antipsychotics, such as aripiprazole and risperidone, are often used to treat individuals with schizophrenia." | 5.19 | Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. ( Gu, N; Kane, JM; Li, H; Luo, J; Wang, C; Wang, X; Xie, S; Xu, X; Yu, W, 2014) |
| "We sought to assess the effect of the addition of a fixed dose of 5 mg daily of aripiprazole on hyperprolactinemia induced by risperidone long-acting injectable (RLAI) treatment in patients with chronic psychoses and the adverse events related to the addition of aripiprazole and its impact on the disease." | 5.17 | Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. ( Bonete Llácer, JM; García Escudero, MA; Martínez Pastor, CJ; Ziadi Trives, M, 2013) |
| " The objective of this study was to determine the prevalence of low BMD in patients with schizophrenia treated with conventional antipsychotics or risperidone and to evaluate any potential relationship with treatment." | 5.17 | Bone loss associated with hyperprolactinemia in patients with schizophrenia. ( Jacob, J; Kinon, BJ; Liu-Seifert, H; Stauffer, VL, 2013) |
| "From December 2004 through March 2008, adult outpatients with a Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition diagnosis of schizophrenia or schizoaffective disorder who were taking haloperidol decanoate (n = 40) or fluphenazine decanoate (n = 22) were randomly assigned to stay on current long-acting injectable medication or switch to risperidone microspheres and followed for 6 months under study protocol and an additional 6 months naturalistic follow-up." | 5.16 | Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. ( Covell, NH; Essock, SM; Jackson, CT; McEvoy, JP; Rojas, IA; Schooler, NR; Stroup, TS, 2012) |
| "In this 6-week, multicenter, randomized, rater single-blind study, a total of 119 patients with schizophrenia were randomly assigned to quetiapine (n = 60, 750 mg/day) or risperidone (n = 59, 4 mg/day)." | 5.16 | Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study. ( Li, H; Li, Y; Liu, Y; Qian, M; Yan, X; Yue, Y, 2012) |
| "Hyperprolactinemia, an adverse effect associated with the use of typical antipsychotics and the atypical antipsychotic risperidone, has both acute and chronic clinical consequences." | 5.14 | Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. ( Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R, 2009) |
| "The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design." | 5.14 | Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. ( Bahk, WM; Cho, HS; Jeon, YW; Jon, DI; Jung, HY; Kim, CH; Kim, HC; Kim, SH; Kim, YH; Kim, YK; Kwon, JS; Lee, SH; Lee, SY; Yang, J; Yi, JS; Yoon, BH, 2010) |
| "To compare the efficacy and tolerability of quetiapine and risperidone in the treatment of schizophrenia." | 5.12 | Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. ( Hamer, RM; Lieberman, JA; Sweitzer, DE; Zhong, KX, 2006) |
| "2 years) inpatients with depressive and anxiety disorders who were treated with risperidone (median doses per day 1." | 5.12 | Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia. ( Bares, M; Horacek, J; Kopecek, M; Mohr, P, 2006) |
| "The goal of this study was to compare the effect of risperidone and haloperidol on serum PRL and investigate the relationship between serum PRL levels and clinical response in patients with schizophrenia." | 5.11 | Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2005) |
| " Thus, we compared ziprasidone and risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder." | 5.11 | Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. ( Addington, DE; Benattia, I; Dineen, M; Pantelis, C; Romano, SJ, 2004) |
| "The prevalence of hyperprolactinemia during treatment with conventional antipsychotic drugs or risperidone is under-recognized and requires further investigation." | 5.10 | Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. ( Gilmore, JA; Halbreich, UM; Kinon, BJ; Liu, H, 2003) |
| "This study was conducted to prospectively examine the effect of switching from risperidone to olanzapine on female schizophrenia patients who experienced menstrual disturbances, galactorrhea, and/or sexual dysfunction." | 5.10 | Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. ( Bahk, WM; Chae, JH; Dickson, RA; Jun, TY; Kim, DJ; Kim, KS; Pae, CU, 2002) |
| "Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children." | 4.81 | Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. ( Biederman, J; Cohen, LG, 2001) |
| " Risperidone is associated with relatively few motor side effects compared with the traditional antipsychotics, and weight gain is less likely with risperidone than with either clozapine or olanzapine." | 4.80 | Risperidone side effects. ( Conley, RR, 2000) |
| " Peak prolactin levels/any hyperprolactinemia/triple-upper-limit-of-normal-prolactin level were highest with risperidone (median = 56." | 4.31 | Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study. ( Carlson, HE; Correll, CU; Kazimi, MM; Koch, MT, 2023) |
| "46); risperidone related to higher risk of hyperprolactinemia (OR: 12." | 4.31 | Therapeutic outcomes wide association scan of different antipsychotics in patients with schizophrenia: Randomized clinical trials and multi-ancestry validation. ( Feng, X; Kang, Z; Liao, Y; Lu, T; Lu, Z; Sun, Y; Wang, L; Yan, H; Yue, W; Zhang, D; Zhang, Y, 2023) |
| "Risperidone and amisulpride caused hyperprolactinemia and macroprolactinemia; thus, detection of MPRL in the clinical setting should be performed as this phenomenon appears early in treatment (the second week) and continues, that can avoid unnecessary examination and treatment for asymptomatic patients with macroprolactinemia." | 4.12 | Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride. ( Haiying, J; Haizhi, C; Jianhua, L; Jianjun, L; Jing, L; Lilei, L; Xiaocong, F; Zhenhua, W, 2022) |
| "We found very common hyperprolactinemia and hypoprolactinemia in the risperidone or paliperidone group and aripiprazole group, respectively." | 4.02 | Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. ( Shimoda, K; Shinozaki, M; Sugawara, N; Tasaki, M; Yasui-Furukori, N; Yokoyama, S, 2021) |
| "The aim of this study was to explore the effectiveness and tolerability of long-acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients while comparing the results with the oral antipsychotic risperidone." | 3.91 | Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients. ( Gačo, N; Graovac, M; Kaštelan, A; Petrić, D; Rački, V, 2019) |
| "We found that the two hyperprolactinemia-inducing antipsychotics, risperidone and pimozide, prompted precancerous lesions to progress to cancer while aripiprazole, which did not cause hyperprolactinemia, did not." | 3.88 | Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. ( Bu, W; Camacho, L; Garcia, S; Hein, S; Hilsenbeck, SG; Johnston, AN; Kapali, J; Li, Y; Nagi, C; Nangia, J; Podsypanina, K; Qin, L; Xue, L, 2018) |
| "The aim of this study was to investigate the association of drug-metabolizing enzyme and transporter (DMET) polymorphisms with the risperidone-induced prolactin response using an overlapping gene model between serum prolactin level and hyperprolactinemia in autism spectrum disorder (ASD) patients." | 3.88 | UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder. ( Chamnanphon, M; Hongkaew, Y; Limsila, P; Medhasi, S; Ngamsamut, N; Pasomsub, E; Puangpetch, A; Sukasem, C; Suthisisang, C; Vanwong, N; Wilffert, B, 2018) |
| "This study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in Han Chinese women with schizophrenia." | 3.83 | Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. ( Guo, Q; Li, C; Ouyang, Q; Qiao, Y; Shen, W; Sheng, J; Wen, H; Yang, F; Zhu, S, 2016) |
| "Hyperprolactinemia is commonly seen in patients with schizophrenia on risperidone." | 3.83 | Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia. ( Chandrasekaran, A; Charan, A; Rajkumar, RP; Shewade, DG, 2016) |
| "In children and adolescents treated with risperidone, hyperprolactinemia is a frequent complication that may have clinical repercussions." | 3.81 | Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects. ( Celeri, EH; Dalgalarrondo, P; de Mello, MP; Della Torre, OH; dos Santos Júnior, A; Ferreira Neto, AP; Fontana, TS; Guerra Júnior, G; Henriques, TB; Paes, LA; Sewaybricker, LE, 2015) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 3.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| " Prolactin levels, hyperprolactinemia, risperidone levels, and 9-hydroxyrisperidone levels were assessed and the participants were genotyped for common CYP2D6 polymorphisms and the Taq1A allele of the dopamine D2 receptor gene." | 3.79 | The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. ( Boot, AM; Buitelaar, JK; Franke, B; Galesloot, TE; Roke, Y; van Harten, PN, 2013) |
| "Hyperprolactinemia is a common side effect in young males treated over the long term with risperidone." | 3.78 | Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. ( Boot, AM; Buitelaar, JK; Roke, Y; Tenback, D; van Harten, PN, 2012) |
| "There have been several case reports of risperidone-associated dysphagia." | 3.77 | Risperidone-induced bulbar palsy-like syndrome. ( Patwa, H; Sico, JJ, 2011) |
| " Inter-individual variability in hyperprolactinemia induced antipsychotics particularly risperidone can be explained by smoking status to some extent." | 3.77 | The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. ( Furukori, H; Kaneko, S; Nakagami, T; Ohta, C; Saito, M; Tsuchimine, S; Yasui-Furukori, N; Yoshizawa, K, 2011) |
| "In subproject Ι, 45 patients receiving the 2nd generation antipsychotics risperidone, clozapine or olanzapine were compared regarding prolactin (PRL), body mass index (BMI), insulin, homeostasis model assessment of insulin resistance (HOMA-IR) and blood lipids." | 3.77 | Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses. ( Berinder, K; Hulting, AL; Melkersson, K, 2011) |
| "The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents." | 3.76 | A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. ( Calarge, CA; Kuperman, S; Schlechte, JA; Xie, D; Zimmerman, B, 2010) |
| "In this study, 11 healthy male subjects taking different doses of sulpiride and 24 male patients with DSM-IV-diagnosed schizophrenia taking different antipsychotic drugs (risperidone, olanzapine, haloperidol, and sulpiride) participated." | 3.76 | Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. ( Arakawa, R; Ito, H; Maeda, J; Okubo, Y; Okumura, M; Suhara, T; Takahashi, H; Takano, A; Takano, H, 2010) |
| "Hyperprolactinemia is associated with typical antipsychotic agents and atypical antipsychotics such as risperidone and amisulpride." | 3.76 | Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. ( Chen, CK; Hsiao, CC; Huang, YS; Ree, SC, 2010) |
| "Hyperprolactinemia is a frequent consequence of treatment with risperidone." | 3.76 | Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. ( Fujii, A; Furukori, H; Kaneko, S; Sugawara, N; Yasui-Furukori, N, 2010) |
| "To investigate the association between hyperprolactinemia and variants of the dopamine D2 receptor (DRD2) gene in children and adolescents in long-term treatment with risperidone." | 3.75 | Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. ( Acion, L; Calarge, CA; Ellingrod, VL; Miller, DD; Moline, J; Schlechte, JA; Tansey, MJ, 2009) |
| "Hyperprolactinemia can be a complication of conventional neurolepics as well as risperidone." | 3.75 | Attenuation of risperidone-induced hyperprolactinemia with the addition of aripiprazole. ( Capote, HA; Gengo, FM; Rainka, MM; Ross, CA, 2009) |
| " The hyperprolactinemia was due to prolonged treatment with the anti-dopaminergic neuroleptic risperidone in Case 1, and chronic renal failure in Case 2." | 3.74 | Radioiodine uptake in non-lactating mammary glands: evidence for a causative role of hyperprolactinemia. ( Bruno, R; Calcinaro, F; Colandrea, M; Durante, C; Filetti, S; Maranghi, M; Montesano, T; Puxeddu, E; Ronga, G; Russo, D; Travascio, L, 2007) |
| "Blood samples taken from 25 patients with psychotic disorders following 6 weeks of treatment with risperidone (mean dose=3 mg/day) were examined." | 3.73 | Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. ( Baselmans, P; Bosker, F; Bruggeman, R; Castelein, S; Knegtering, R; van den Bosch, RJ, 2005) |
| "Treatment with risperidone was frequently associated with hyperprolactinemia and related symptoms, whereas the occurrence of PRL elevation and related symptoms was modest in patients receiving olanzapine and nonexistent in those receiving clozapine." | 3.73 | Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. ( Melkersson, K, 2005) |
| "Studies performed in adult patients unambiguously demonstrate a marked effect of risperidone on prolactin blood levels, with possible clinical effects related to hyperprolactinemia, such as gynecomastia and galactorrhea." | 3.73 | Risperidone-induced symptomatic hyperprolactinaemia in adolescents. ( Eap, CB; Holzer, L, 2006) |
| " Risperidone had the highest adjusted reporting ratios for hyperprolactinemia (EBGM 34." | 3.73 | Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. ( Doraiswamy, PM; Levine, JG; Szarfman, A; Tonning, JM, 2006) |
| "Prolactin levels returned to normal, and clinical symptoms of hyperprolactinemia resolved in all 3 patients after 2 weeks of tapering and discontinuation of risperidone." | 3.73 | Risperidone-induced hyperprolactinemia in adolescents: A case series. ( Madhusoodanan, S; Moise, D, 2006) |
| "To report a case of risperidone-induced hyperprolactinemia that was successfully managed with quetiapine." | 3.72 | Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine. ( Kunwar, AR; Megna, JL, 2003) |
| "Factors that influenced the risk of hyperprolactinemia included gender, with females appearing to be more sensitive than males, and drug treatment, with risperidone and conventional antipsychotic agents increasing prolactin more than olanzapine." | 3.72 | Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. ( Gilmore, JA; Halbreich, UM; Kinon, BJ; Liu, H, 2003) |
| "Nineteen male and female DSM-IV-defined schizophrenic patients who were clinical responders to risperidone but were suffering from symptomatic hyperprolactinemia were treated with cabergoline, 0." | 3.72 | Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. ( Angelone, SM; Cavallaro, R; Cocchi, F; Lattuada, E; Smeraldi, E, 2004) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 3.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "Several years ago, we reported that the addition of risperidone to clozapine improved response in some patients with schizophrenia." | 3.71 | Risperidone added to clozapine: impact on serum prolactin levels. ( Borba, CP; Connolly, CE; Goff, DC; Hayden, D; Henderson, DC, 2001) |
| "Although hyperprolactinemia is a common side effect during risperidone treatment in adult patients, no information is available on young children." | 3.71 | Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. ( Cosenza, A; Masi, G; Mucci, M, 2001) |
| " Overall, 63 (94%) patients experienced at least one treatment-emergent adverse event (TEAE)." | 2.87 | A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. ( Anta, L; Ayani, I; Gutierro, I; Litman, RE; Llaudó, J; Martínez, J, 2018) |
| " Prolactin levels could assist in the determination of appropriate antipsychotic dosing to minimize adverse effects." | 2.82 | Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. ( Caravaggio, F; Chung, JK; Gerretsen, P; Graff-Guerrero, A; Iwata, Y; Mamo, DC; Mar, W; Mulsant, BH; Nakajima, S; Plitman, E; Pollock, BG; Rajji, TK; Suzuki, T; Uchida, H, 2016) |
| " However, the ideal dosing regimen for this purpose is unknown." | 2.80 | Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. ( Bian, QT; Chen, JX; Correll, C; Liu, YH; Soares, JC; Su, YA; Wang, SL; Wei, LH; Yang, FD; Zhang, RZ; Zhang, XY, 2015) |
| "This was a 6-week, multicenter, randomized, open-label, parallel-group, flexible dosing study." | 2.78 | An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. ( Chan, HY; Chen, KP; Chen, YY; Cheng, JS; Lin, AS; Tsai, CJ, 2013) |
| "Risperidone was significantly more likely to be associated with elevation in serum prolactin levels in this population." | 2.75 | A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. ( Black, VC; Bobier, CM; Buchan, JC; Craig, BJ; Pirwani, NZ; Swadi, HS, 2010) |
| "Hyperprolactinemia is an important but neglected adverse effect of antipsychotic medication." | 2.73 | Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. ( Chen, CH; Lu, ML; Shen, WW, 2008) |
| "The trial was a prospective, open-label, single-center one with a flexible dosing of SGAs." | 2.73 | Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. ( Cejpková, A; Rodáková, I; Svestka, J; Synek, O; Tomanová, J, 2007) |
| "Hyperprolactinemia is a common adverse effect that occurs as a result of antipsychotic therapies, which often results in discontinuation." | 2.73 | A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. ( Feng, XJ; Liu, RM; Sze, CW; Tan, QR; Tong, Y; Wang, CY; Yuan, HN; Zhang, JZ; Zhang, YB; Zhang, ZJ, 2008) |
| "Preschool children tolerated low-dose risperidone well with no serious adverse effects observed over a 6-month treatment period." | 2.72 | Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. ( Belden, A; Heffelfinger, A; Luby, J; Mrakotsky, C; Spitznagel, E; Stalets, MM; Williams, M, 2006) |
| "RLAI and OP show good short- and long-term safety when treating patients with schizophrenia, with uncommon discontinuation due to adverse effects." | 2.46 | Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. ( Cañas, F; Möller, HJ, 2010) |
| "Five new antipsychotic drugs introduced in the United States in the last decade offer physicians the ability to treat patients with schizophrenia and bipolar mania without the adverse effects of the first-generation antipsychotics." | 2.42 | The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. ( Citrome, L; Volavka, J, 2004) |
| "Hyperprolactinemia was found in 120 (70." | 1.56 | Prolactin response to antipsychotics: An inpatient study. ( Bredicean, CA; Dehelean, L; Dumitrascu, V; Papava, I; Romosan, AM; Romosan, RS; Ursoniu, S, 2020) |
| "The aim of the study is to find a relationship between the individual intervariability of CYP2D6 and the incidence of hyperprolactinemia as side effect of atypical antipsychotics." | 1.51 | Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients. ( Andreescu, N; Grădinaru, R; Nussbaum, L; Puiu, M; Suciu, L, 2019) |
| "Risperidone is known to increase prolactin secretion in treating mental illness patients." | 1.46 | The central mechanism of risperidone-induced hyperprolactinemia. ( Huang, XF; Li, LY; Lin, S; Shi, YC; Song, ZY; Sun, WW; Yang, HQ, 2017) |
| "The prevalence of hyperprolactinaemia in this population (n=67, 13%) was higher than in the general population." | 1.43 | Prolactin monitoring in the acute psychiatry setting. ( Goldring, KJ; Menon, SJ; Perry, BI, 2016) |
| "These results suggest that hyperprolactinaemia may develop during risperidone treatment." | 1.43 | 9-Hydroxyrisperidone-Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder. ( Chamkrachangpada, B; Hongkaew, Y; Limsila, P; Ngamsamut, N; Puangpetch, A; Srisawasdi, P; Sukasem, C; Tan-Khum, T; Vanwong, N, 2016) |
| " The mean serum PRL was higher in females in the pubertal/postpubertal stage and for risperidone dosage up 1 mg/day." | 1.42 | Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents. ( Lamanna, AL; Margari, F; Margari, L; Matera, E; Palmieri, VO; Pastore, A; Petruzzelli, MG; Simone, M, 2015) |
| "Hyperprolactinaemia is a significant side effect of antipsychotic medications and may cause sexual dysfunction." | 1.39 | Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. ( Franch, J; Labad, J; López, X; Monseny, R; Montalvo, I; Ortega, L; Solé, M; Vilella, E, 2013) |
| "Risperidone (n=63) treated patients had higher AUDIT scores and prolactin levels than those on other atypical antipsychotics (n = 113)." | 1.38 | Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia. ( Barnes, M; Connor, JP; Heslop, K; Lawford, BR; Nyst, P; Young, RM, 2012) |
| "Medicamentous hyperprolactinaemia is a well known side effect of risperidone." | 1.36 | Hyperprolactinaemia - a risperidone side-effect. ( Dadić-Hero, E; Grahovac, T; Medved, P; Pavesić-Radonja, A; Ruzić, K, 2010) |
| " Prolactin concentrations before dosing during risperidone treatment were significantly higher than during treatment with olanzapine and perospirone in females." | 1.36 | Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients. ( Fujii, A; Furukori, H; Inoue, Y; Kaneko, S; Sugawara, N; Tsuchimine, S; Yasui-Furukori, N, 2010) |
| "Risperidone (N=45, 62%) was the most frequently prescribed antipsychotic drug, followed by olanzapine (24, 32%)." | 1.35 | Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting. ( Alacqua, M; Arcoraci, V; Calarese, T; Di Vita, G; Gagliano, C; Germanò, E; Magazù, A; Spina, E; Trifirò, G, 2008) |
| "Risperidone monotherapy treatment was associated with hyperprolactinaemia in 69% of patients ( n = 35) and in 100% of female patients (n = 16) and amisulpride monotherapy in 100% (n = 7)." | 1.34 | Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. ( Bushe, C; Shaw, M, 2007) |
| " However, no correlation between prolactin levels and dosage could be found." | 1.32 | [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics]. ( Fric, M; Laux, G, 2003) |
| "Hyperprolactinemia is a side effect related to antipsychotics that can cause galactorrhea, gynecomastia, amenorrhea, anovulation, impaired spermatogenesis, decreased libido and sexual arousal, impotence, and anorgasmia, consequent to removal of tonic dopaminergic inhibition of prolactin secretion via hypothalamic dopaminergic receptor blockade in the tuberoinfundibolar tract." | 1.31 | Switch to quetiapine in antipsychotic agent-related hyperprolactinemia. ( Keller, R; Mongini, F, 2002) |
| "Risperidone (3 microM) was found to slow the rate of activation." | 1.31 | Characterization of inhibition by risperidone of the inwardly rectifying K(+) current in pituitary GH(3) cells. ( Chiang, HT; Jan, CR; Li, HF; Wu, SN, 2000) |
| "Risperidone is a novel antipsychotic agent that blocks both dopaminergic and serotonergic receptors." | 1.31 | Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. ( Tollin, SR, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (2.16) | 18.2507 |
| 2000's | 64 (46.04) | 29.6817 |
| 2010's | 63 (45.32) | 24.3611 |
| 2020's | 9 (6.47) | 2.80 |
| Authors | Studies |
|---|---|
| Lange, JH | 1 |
| Reinders, JH | 1 |
| Tolboom, JT | 1 |
| Glennon, JC | 1 |
| Coolen, HK | 1 |
| Kruse, CG | 1 |
| Gao, L | 1 |
| Hao, C | 1 |
| Chen, J | 1 |
| Ma, R | 1 |
| Zheng, L | 1 |
| Wu, Q | 1 |
| Liu, X | 1 |
| Liu, BF | 1 |
| Zhang, G | 1 |
| Chen, Y | 1 |
| Jin, J | 1 |
| Biswas, M | 1 |
| Vanwong, N | 3 |
| Sukasem, C | 3 |
| Koch, MT | 1 |
| Carlson, HE | 1 |
| Kazimi, MM | 1 |
| Correll, CU | 2 |
| Strawn, JR | 1 |
| Geracioti, TD | 1 |
| Lu, Z | 1 |
| Zhang, Y | 1 |
| Sun, Y | 1 |
| Liao, Y | 1 |
| Kang, Z | 1 |
| Feng, X | 1 |
| Yan, H | 1 |
| Wang, L | 1 |
| Lu, T | 2 |
| Zhang, D | 1 |
| Yue, W | 1 |
| Dehelean, L | 1 |
| Romosan, AM | 1 |
| Papava, I | 1 |
| Bredicean, CA | 1 |
| Dumitrascu, V | 1 |
| Ursoniu, S | 1 |
| Romosan, RS | 1 |
| Zhenhua, W | 1 |
| Haizhi, C | 1 |
| Jing, L | 1 |
| Xiaocong, F | 1 |
| Jianhua, L | 1 |
| Jianjun, L | 1 |
| Lilei, L | 1 |
| Haiying, J | 1 |
| Rush Ortegon, E | 1 |
| Ferguson, J | 1 |
| Coffey, BJ | 2 |
| Tasaki, M | 1 |
| Yasui-Furukori, N | 4 |
| Yokoyama, S | 1 |
| Shinozaki, M | 1 |
| Sugawara, N | 3 |
| Shimoda, K | 1 |
| Sun, WW | 1 |
| Li, LY | 1 |
| Huang, XF | 1 |
| Shi, YC | 1 |
| Yang, HQ | 1 |
| Song, ZY | 1 |
| Lin, S | 1 |
| Boothby, A | 1 |
| Shad, MU | 1 |
| Anta, L | 1 |
| Llaudó, J | 1 |
| Ayani, I | 1 |
| Martínez, J | 1 |
| Litman, RE | 1 |
| Gutierro, I | 1 |
| Calarge, CA | 3 |
| Mills, JA | 1 |
| Ziegler, EE | 1 |
| Schlechte, JA | 3 |
| Johnston, AN | 1 |
| Bu, W | 1 |
| Hein, S | 1 |
| Garcia, S | 1 |
| Camacho, L | 1 |
| Xue, L | 1 |
| Qin, L | 1 |
| Nagi, C | 1 |
| Hilsenbeck, SG | 1 |
| Kapali, J | 1 |
| Podsypanina, K | 1 |
| Nangia, J | 1 |
| Li, Y | 2 |
| Hongkaew, Y | 2 |
| Medhasi, S | 1 |
| Pasomsub, E | 1 |
| Ngamsamut, N | 2 |
| Puangpetch, A | 2 |
| Chamnanphon, M | 1 |
| Limsila, P | 2 |
| Suthisisang, C | 1 |
| Wilffert, B | 1 |
| Mazher, OA | 1 |
| Maneta, E | 1 |
| Hall, W | 1 |
| Petrić, D | 1 |
| Rački, V | 1 |
| Gačo, N | 1 |
| Kaštelan, A | 1 |
| Graovac, M | 1 |
| Grădinaru, R | 1 |
| Andreescu, N | 1 |
| Nussbaum, L | 1 |
| Suciu, L | 1 |
| Puiu, M | 1 |
| Schmidt, M | 1 |
| Sofronescu, A | 1 |
| Short, B | 1 |
| Nahas, Z | 1 |
| Zhu, Y | 1 |
| Ruocco, E | 1 |
| Brunetti, G | 1 |
| Langella, GG | 1 |
| Ruocco, V | 1 |
| Voicu, V | 1 |
| Medvedovici, A | 1 |
| Ranetti, AE | 1 |
| Rădulescu, FŞ | 1 |
| Tsuboi, T | 1 |
| Bies, RR | 1 |
| Suzuki, T | 2 |
| Mamo, DC | 2 |
| Pollock, BG | 2 |
| Graff-Guerrero, A | 2 |
| Mimura, M | 1 |
| Uchida, H | 2 |
| Ziadi Trives, M | 1 |
| Bonete Llácer, JM | 1 |
| García Escudero, MA | 1 |
| Martínez Pastor, CJ | 1 |
| Kalkavoura, CS | 1 |
| Michopoulos, I | 1 |
| Arvanitakis, P | 1 |
| Theodoropoulou, P | 1 |
| Dimopoulou, K | 1 |
| Tzebelikos, E | 1 |
| Lykouras, L | 1 |
| Roke, Y | 2 |
| van Harten, PN | 2 |
| Franke, B | 1 |
| Galesloot, TE | 1 |
| Boot, AM | 2 |
| Buitelaar, JK | 2 |
| Chan, HY | 1 |
| Lin, AS | 1 |
| Chen, KP | 1 |
| Cheng, JS | 1 |
| Chen, YY | 1 |
| Tsai, CJ | 2 |
| Lozano, R | 1 |
| Marin, R | 1 |
| Santacruz, MJ | 1 |
| Li, H | 2 |
| Luo, J | 1 |
| Wang, C | 2 |
| Xie, S | 1 |
| Xu, X | 1 |
| Wang, X | 1 |
| Yu, W | 1 |
| Gu, N | 1 |
| Kane, JM | 1 |
| Margari, L | 1 |
| Matera, E | 1 |
| Petruzzelli, MG | 1 |
| Simone, M | 1 |
| Lamanna, AL | 1 |
| Pastore, A | 1 |
| Palmieri, VO | 1 |
| Margari, F | 1 |
| Chen, JX | 2 |
| Su, YA | 2 |
| Bian, QT | 2 |
| Wei, LH | 1 |
| Zhang, RZ | 1 |
| Liu, YH | 2 |
| Correll, C | 1 |
| Soares, JC | 1 |
| Yang, FD | 2 |
| Wang, SL | 2 |
| Zhang, XY | 3 |
| Hu, LY | 1 |
| Lee, YT | 1 |
| Hung, MB | 1 |
| Hung, YY | 1 |
| Zhao, J | 1 |
| Song, X | 1 |
| Ai, X | 1 |
| Gu, X | 1 |
| Huang, G | 1 |
| Li, X | 2 |
| Pang, L | 1 |
| Ding, M | 1 |
| Ding, S | 1 |
| Lv, L | 1 |
| Perry, BI | 1 |
| Goldring, KJ | 1 |
| Menon, SJ | 1 |
| dos Santos Júnior, A | 1 |
| Henriques, TB | 1 |
| de Mello, MP | 1 |
| Ferreira Neto, AP | 1 |
| Paes, LA | 1 |
| Della Torre, OH | 1 |
| Sewaybricker, LE | 1 |
| Fontana, TS | 1 |
| Celeri, EH | 1 |
| Guerra Júnior, G | 1 |
| Dalgalarrondo, P | 1 |
| Srisawasdi, P | 1 |
| Chamkrachangpada, B | 1 |
| Tan-Khum, T | 1 |
| Qiao, Y | 1 |
| Yang, F | 1 |
| Li, C | 1 |
| Guo, Q | 1 |
| Wen, H | 1 |
| Zhu, S | 1 |
| Ouyang, Q | 1 |
| Shen, W | 1 |
| Sheng, J | 1 |
| Potanin, SS | 1 |
| Burminskiy, DS | 1 |
| Morozova, MA | 1 |
| Platova, AI | 1 |
| Baymeeva, NV | 1 |
| Miroshnichenko, II | 1 |
| Park, YM | 1 |
| Lee, SH | 2 |
| Lee, BH | 1 |
| Lee, KY | 1 |
| Lee, KS | 1 |
| Kang, SG | 1 |
| Lee, HY | 1 |
| Kim, W | 1 |
| Charan, A | 1 |
| Shewade, DG | 1 |
| Rajkumar, RP | 1 |
| Chandrasekaran, A | 1 |
| Kim, E | 1 |
| Mao, L | 1 |
| Starr, HL | 1 |
| Alphs, L | 1 |
| An, FR | 1 |
| Yang, R | 1 |
| Wang, ZM | 1 |
| Ungvari, GS | 1 |
| Ng, CH | 1 |
| Chiu, HF | 1 |
| Wu, PP | 1 |
| Jin, X | 1 |
| Li, L | 1 |
| Lok, GK | 1 |
| Xiang, YT | 1 |
| Bo, Q | 1 |
| Dong, F | 1 |
| Wang, Z | 1 |
| Ma, X | 1 |
| Wallach, JD | 1 |
| Sullivan, PG | 1 |
| Trepanowski, JF | 1 |
| Steyerberg, EW | 1 |
| Ioannidis, JP | 1 |
| Iwata, Y | 1 |
| Nakajima, S | 1 |
| Caravaggio, F | 1 |
| Plitman, E | 1 |
| Chung, JK | 1 |
| Mar, W | 1 |
| Gerretsen, P | 1 |
| Mulsant, BH | 1 |
| Rajji, TK | 1 |
| Konarzewska, B | 1 |
| Wołczyński, S | 1 |
| Szulc, A | 1 |
| Galińska, B | 1 |
| Popławska, R | 1 |
| Waszkiewicz, N | 1 |
| Lu, ML | 1 |
| Shen, WW | 1 |
| Chen, CH | 2 |
| Peng, PW | 1 |
| Huang, MC | 2 |
| Pan, CH | 1 |
| Chen, CC | 1 |
| Chiu, CC | 1 |
| Byerly, MJ | 1 |
| Marcus, RN | 1 |
| Tran, QV | 1 |
| Eudicone, JM | 1 |
| Whitehead, R | 1 |
| Baker, RA | 1 |
| Tschoner, A | 1 |
| Engl, J | 1 |
| Rettenbacher, MA | 1 |
| Kaser, S | 1 |
| Ott, HW | 1 |
| Fleischhacker, WW | 1 |
| Patsch, JR | 1 |
| Ebenbichler, CF | 1 |
| Ellingrod, VL | 1 |
| Acion, L | 1 |
| Miller, DD | 1 |
| Moline, J | 1 |
| Tansey, MJ | 1 |
| Monge Galindo, L | 1 |
| Escosa García, L | 1 |
| García Sánchez, N | 1 |
| Ruiz-Lázaro, PM | 1 |
| Wang, N | 1 |
| Haile, C | 1 |
| Kosten, TR | 1 |
| Rainka, MM | 1 |
| Capote, HA | 1 |
| Ross, CA | 1 |
| Gengo, FM | 1 |
| Swadi, HS | 1 |
| Craig, BJ | 1 |
| Pirwani, NZ | 1 |
| Black, VC | 1 |
| Buchan, JC | 1 |
| Bobier, CM | 1 |
| Jummani, R | 1 |
| Mishra, AC | 1 |
| Mohanty, B | 1 |
| Grahovac, T | 1 |
| Ruzić, K | 1 |
| Medved, P | 1 |
| Pavesić-Radonja, A | 1 |
| Dadić-Hero, E | 1 |
| Peitl, MV | 1 |
| Pavlović, E | 1 |
| Peitl, A | 1 |
| Peitl, V | 1 |
| Zimmerman, B | 1 |
| Xie, D | 1 |
| Kuperman, S | 1 |
| Arakawa, R | 1 |
| Okumura, M | 1 |
| Ito, H | 1 |
| Takano, A | 1 |
| Takahashi, H | 1 |
| Takano, H | 1 |
| Maeda, J | 1 |
| Okubo, Y | 1 |
| Suhara, T | 1 |
| Furukori, H | 3 |
| Tsuchimine, S | 2 |
| Fujii, A | 2 |
| Inoue, Y | 1 |
| Kaneko, S | 3 |
| Yang, J | 1 |
| Bahk, WM | 2 |
| Cho, HS | 1 |
| Jeon, YW | 1 |
| Jon, DI | 1 |
| Jung, HY | 1 |
| Kim, CH | 1 |
| Kim, HC | 1 |
| Kim, YK | 1 |
| Kim, YH | 1 |
| Kwon, JS | 1 |
| Lee, SY | 1 |
| Yi, JS | 1 |
| Yoon, BH | 1 |
| Kim, SH | 1 |
| Cañas, F | 1 |
| Möller, HJ | 1 |
| Chen, CK | 2 |
| Huang, YS | 1 |
| Ree, SC | 1 |
| Hsiao, CC | 1 |
| Sico, JJ | 1 |
| Patwa, H | 1 |
| Ng, KW | 1 |
| Lee, J | 1 |
| Swapna, V | 1 |
| van Kooten, M | 1 |
| Arends, J | 1 |
| Cohen, D | 1 |
| Ohta, C | 1 |
| Saito, M | 1 |
| Nakagami, T | 1 |
| Yoshizawa, K | 1 |
| Lawford, BR | 2 |
| Barnes, M | 2 |
| Connor, JP | 1 |
| Heslop, K | 1 |
| Nyst, P | 1 |
| Young, RM | 2 |
| Ishitobi, M | 2 |
| Kosaka, H | 2 |
| Shukunami, K | 2 |
| Murata, T | 2 |
| Wada, Y | 2 |
| Lin, CH | 2 |
| Ma, H | 1 |
| Chung, MT | 1 |
| Chou, J | 2 |
| Melkersson, K | 2 |
| Berinder, K | 1 |
| Hulting, AL | 1 |
| Hsu, CW | 1 |
| Tsao, TY | 1 |
| Covell, NH | 1 |
| McEvoy, JP | 1 |
| Schooler, NR | 1 |
| Stroup, TS | 1 |
| Jackson, CT | 1 |
| Rojas, IA | 1 |
| Essock, SM | 1 |
| Anandarajan, T | 1 |
| Tibrewal, P | 1 |
| Dhillon, R | 1 |
| Bastiampillai, T | 1 |
| Howland, RH | 1 |
| Liu, Y | 1 |
| Yan, X | 1 |
| Yue, Y | 1 |
| Qian, M | 1 |
| Montalvo, I | 1 |
| Ortega, L | 1 |
| López, X | 1 |
| Solé, M | 1 |
| Monseny, R | 1 |
| Franch, J | 1 |
| Vilella, E | 1 |
| Labad, J | 1 |
| Tenback, D | 1 |
| Kinon, BJ | 4 |
| Liu-Seifert, H | 2 |
| Stauffer, VL | 1 |
| Jacob, J | 1 |
| Canuso, CM | 2 |
| Goldstein, JM | 1 |
| Wojcik, J | 1 |
| Dawson, R | 1 |
| Brandman, D | 1 |
| Klibanski, A | 1 |
| Schildkraut, JJ | 1 |
| Green, AI | 2 |
| Denisov, MF | 1 |
| Bai, YM | 2 |
| Ciu, HJ | 1 |
| Guo, ZZ | 1 |
| Valiquette, G | 1 |
| Keller, R | 1 |
| Mongini, F | 1 |
| Kunwar, AR | 1 |
| Megna, JL | 1 |
| Gilmore, JA | 2 |
| Liu, H | 2 |
| Halbreich, UM | 2 |
| Gupta, S | 1 |
| Holtmann, M | 1 |
| Gerstner, S | 1 |
| Schmidt, MH | 1 |
| Brunelleschi, S | 1 |
| Zeppegno, P | 1 |
| Risso, F | 1 |
| Cattaneo, CI | 1 |
| Torre, E | 1 |
| Fric, M | 1 |
| Laux, G | 1 |
| Meaney, AM | 1 |
| O'Keane, V | 1 |
| Cavallaro, R | 1 |
| Cocchi, F | 1 |
| Angelone, SM | 1 |
| Lattuada, E | 1 |
| Smeraldi, E | 1 |
| Dossenbach, M | 1 |
| Erol, A | 1 |
| el Mahfoud Kessaci, M | 1 |
| Shaheen, MO | 1 |
| Sunbol, MM | 1 |
| Boland, J | 1 |
| Hodge, A | 1 |
| O'Halloran, RA | 1 |
| Bitter, I | 1 |
| Burton, SC | 1 |
| Ritchie, T | 1 |
| Ward, WK | 1 |
| Noble, EP | 1 |
| Zhou, DF | 1 |
| Cao, LY | 1 |
| Zhang, PY | 1 |
| Wu, GY | 1 |
| Shen, YC | 1 |
| Lusskin, SI | 1 |
| Cancro, R | 1 |
| Chuang, L | 1 |
| Jacobson, J | 1 |
| Rack, MJ | 1 |
| Baran, AS | 1 |
| Richert, AC | 1 |
| Roffwarg, HP | 1 |
| Citrome, L | 1 |
| Volavka, J | 1 |
| Addington, DE | 1 |
| Pantelis, C | 1 |
| Dineen, M | 1 |
| Benattia, I | 1 |
| Romano, SJ | 1 |
| Ahl, J | 1 |
| Schooler, N | 1 |
| Rabinowitz, J | 1 |
| Davidson, M | 1 |
| Emsley, R | 1 |
| Harvey, PD | 1 |
| Kopala, L | 1 |
| McGorry, PD | 1 |
| Van Hove, I | 1 |
| Eerdekens, M | 1 |
| Swyzen, W | 1 |
| De Smedt, G | 1 |
| Knegtering, R | 1 |
| Baselmans, P | 1 |
| Castelein, S | 1 |
| Bosker, F | 1 |
| Bruggeman, R | 1 |
| van den Bosch, RJ | 1 |
| Wahl, R | 1 |
| Ostroff, R | 1 |
| Hellings, JA | 1 |
| Zarcone, JR | 1 |
| Valdovinos, MG | 1 |
| Reese, RM | 1 |
| Gaughan, E | 1 |
| Schroeder, SR | 1 |
| Stevens, JR | 1 |
| Kymissis, PI | 1 |
| Baker, AJ | 1 |
| Holzer, L | 1 |
| Eap, CB | 1 |
| Szarfman, A | 1 |
| Tonning, JM | 1 |
| Levine, JG | 1 |
| Doraiswamy, PM | 1 |
| Zhong, KX | 1 |
| Sweitzer, DE | 1 |
| Hamer, RM | 1 |
| Lieberman, JA | 1 |
| Madhusoodanan, S | 1 |
| Moise, D | 1 |
| Lin, SK | 1 |
| Lin, CY | 1 |
| Wu, PL | 1 |
| Pariante, CM | 1 |
| Su, KP | 1 |
| Luby, J | 1 |
| Mrakotsky, C | 1 |
| Stalets, MM | 1 |
| Belden, A | 1 |
| Heffelfinger, A | 1 |
| Williams, M | 1 |
| Spitznagel, E | 1 |
| Kopecek, M | 1 |
| Bares, M | 1 |
| Horacek, J | 1 |
| Mohr, P | 1 |
| Ronga, G | 1 |
| Bruno, R | 1 |
| Puxeddu, E | 1 |
| Calcinaro, F | 1 |
| Montesano, T | 1 |
| Travascio, L | 1 |
| Colandrea, M | 1 |
| Durante, C | 1 |
| Maranghi, M | 1 |
| Filetti, S | 1 |
| Russo, D | 1 |
| Chen, TT | 1 |
| Lin, WK | 1 |
| Chang, WH | 1 |
| Wu, B | 1 |
| Hung, CH | 1 |
| Chou, P | 1 |
| Chen, JY | 1 |
| Segal, M | 1 |
| Avital, A | 1 |
| Derevenski, A | 1 |
| Berstein, S | 1 |
| Sandbank, S | 1 |
| Weizman, A | 1 |
| Alacqua, M | 1 |
| Trifirò, G | 1 |
| Arcoraci, V | 1 |
| Germanò, E | 1 |
| Magazù, A | 1 |
| Calarese, T | 1 |
| Di Vita, G | 1 |
| Gagliano, C | 1 |
| Spina, E | 1 |
| Bushe, C | 1 |
| Shaw, M | 1 |
| Lai, YC | 1 |
| Chiou, CC | 1 |
| Perlis, RH | 1 |
| Svestka, J | 1 |
| Synek, O | 1 |
| Tomanová, J | 1 |
| Rodáková, I | 1 |
| Cejpková, A | 1 |
| Yuan, HN | 1 |
| Wang, CY | 1 |
| Sze, CW | 1 |
| Tong, Y | 1 |
| Tan, QR | 1 |
| Feng, XJ | 1 |
| Liu, RM | 1 |
| Zhang, JZ | 1 |
| Zhang, YB | 1 |
| Zhang, ZJ | 1 |
| Dickson, RA | 3 |
| Dalby, JT | 1 |
| Williams, R | 1 |
| Edwards, AL | 1 |
| Hanau, M | 1 |
| Jhamb, KK | 1 |
| Glazer, WM | 1 |
| Conley, RR | 1 |
| Wallmeroth, A | 1 |
| Staub, JJ | 1 |
| Wu, SN | 1 |
| Jan, CR | 1 |
| Li, HF | 1 |
| Chiang, HT | 1 |
| Tollin, SR | 1 |
| Henderson, DC | 1 |
| Goff, DC | 1 |
| Connolly, CE | 1 |
| Borba, CP | 1 |
| Hayden, D | 1 |
| Masi, G | 1 |
| Cosenza, A | 1 |
| Mucci, M | 1 |
| Cohen, LG | 1 |
| Biederman, J | 1 |
| Kim, KS | 1 |
| Pae, CU | 1 |
| Chae, JH | 1 |
| Jun, TY | 1 |
| Kim, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Counteracting Risperidone-Induced Hyperprolactinemia in Youths[NCT00799383] | Phase 3 | 47 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001] | Phase 4 | 1,600 participants | Interventional | 2000-12-31 | Completed | ||
| A Multi-centre Comparative Study to Evaluate the Anti-aggression Effect and Safety of Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward[NCT00418873] | Phase 4 | 39 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Study was stopped due to difficulty in patient enrollment) | ||
| A Randomized Trial to Compare the Efficiency and Side Effect Between Olanzapine and Long-acting Paliperidone Palmitate Injection in Schizophrenia[NCT02918825] | 100 participants (Actual) | Interventional | 2016-09-01 | Completed | |||
| Risperidone Maintenance Treatment for Relapse Prevention in Schizophrenia[NCT00848432] | Phase 4 | 404 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| The Minimal Effective Dose of Antipsychotic Medication in Older Patients With Schizophrenia: a PET Study.[NCT00716755] | 45 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial[NCT00541554] | Phase 4 | 0 participants | Interventional | 2007-10-31 | Not yet recruiting | ||
| Effectiveness of Switching Antipsychotic Medications[NCT00044655] | Phase 4 | 219 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measured at the 4% radius site. (NCT00799383)
Timeframe: 36 weeks
| Intervention | mg^2/mm^4 (Mean) | ||
|---|---|---|---|
| Baseline | week 18 | week 36 | |
| Calcium+VitD | 19.8 | 21.0 | 23.1 |
| Placebo | 25.3 | 22.9 | 26.1 |
This was measured at the 20% radius site. (NCT00799383)
Timeframe: 36 weeks
| Intervention | mg/cm^3 (Mean) | ||
|---|---|---|---|
| Baseline | week 18 | week 36 | |
| Calcium+VitD | 1059.6 | 1062.8 | 1069.3 |
| Placebo | 1063.2 | 1060.2 | 1058.7 |
This was measured at the 20% radius site. (NCT00799383)
Timeframe: 36 weeks
| Intervention | mm (Mean) | ||
|---|---|---|---|
| Baseline | week 18 | week 36 | |
| Calcium+VitD | 2.25 | 2.25 | 2.32 |
| Placebo | 2.34 | 2.26 | 2.34 |
This was measured at the 20% radius site. (NCT00799383)
Timeframe: 36 weeks
| Intervention | mm (Mean) | ||
|---|---|---|---|
| Baseline | week 18 | week 36 | |
| Calcium+VitD | 16.0 | 17.0 | 16.8 |
| Placebo | 17.7 | 18.4 | 17.6 |
This was measured at the 20% radius site. (NCT00799383)
Timeframe: 36 weeks
| Intervention | mm (Mean) | ||
|---|---|---|---|
| Baseline | week 18 | week 36 | |
| Calcium+VitD | 30.1 | 31.2 | 31.4 |
| Placebo | 32.4 | 32.6 | 32.3 |
This was measured at the 20% radius site. (NCT00799383)
Timeframe: 36 weeks
| Intervention | mm^3 (Mean) | ||
|---|---|---|---|
| Baseline | week 18 | week 36 | |
| Calcium+VitD | 123.8 | 134.5 | 137.2 |
| Placebo | 156.2 | 156.8 | 151.9 |
Outcomes were measured at baseline, 18 weeks, and 36 weeks later. (NCT00799383)
Timeframe: 36 weeks
| Intervention | Z score (age-sex-height-race specific) (Mean) | ||
|---|---|---|---|
| At Baseline | At 18 Weeks | At 36 Weeks | |
| Calcium+VitD | 0.10 | 0.24 | 0.20 |
| Placebo | 0.12 | 0.23 | 0.17 |
"Peripheral quantitative computed tomography (pQCT) scan was obtained at the 4% and 20% sites of the nondominant radius to estimate trabecular and cortical BMD, respectively. A Stratec XCT-2000 scanner, software version 6.0 (Stratec, Inc., Pforzheim, Germany),was used. Trabecular BMD was measured as the mean density of the 85% central area of the bone's cross-section.~Outcomes were measured at baseline, 18 weeks, and 36 weeks later." (NCT00799383)
Timeframe: 36 weeks
| Intervention | mg/cm^3 (Mean) | ||
|---|---|---|---|
| Baseline | At 18 Weeks | At 36 Weeks | |
| Calcium+VitD | 192.9 | 191.0 | 195.7 |
| Placebo | 197.2 | 194.6 | 213.1 |
(NCT00044655)
Timeframe: Measured at Six Months
| Intervention | participants (Number) |
|---|---|
| Stay | 11 |
| Switch | 23 |
9 reviews available for risperidone and Hyperprolactinemia
| Article | Year |
|---|---|
Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Humans; Hyperprolactinemia; Pharmacogenetics; Prolac | 2022 |
Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Blood-Brain Barrier; Humans; Hyperprolactinemia; Is | 2013 |
Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses.
Topics: Benzodiazepines; Bias; Carotid Stenosis; Endarterectomy, Carotid; Female; Humans; Hyperprolactinemia | 2016 |
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Dyslipidem | 2010 |
Safety in treating bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Melli | 2003 |
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzoth | 2004 |
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabete | 2007 |
Risperidone side effects.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Inc | 2000 |
Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.
Topics: Age Factors; Antipsychotic Agents; Cabergoline; Child; Dopamine Agonists; Ergolines; Humans; Hyperpr | 2001 |
35 trials available for risperidone and Hyperprolactinemia
| Article | Year |
|---|---|
A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Adm | 2018 |
Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study.
Topics: Absorptiometry, Photon; Adolescent; Antipsychotic Agents; Bone Density; Calcium Carbonate; Calcium, | 2018 |
Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hyperprolactinemia; | 2013 |
Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biomarkers; Chemistry, Pharmaceutical; Drug Administratio | 2013 |
An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dibenzothiepins; Female; Hospitalization; Humans; Hyperp | 2013 |
Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Blood Pressure; China; Diagnostic and Stati | 2014 |
Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blin | 2015 |
Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Aripiprazole; Blood Glu | 2015 |
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazep | 2016 |
Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia.
Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Maint | 2016 |
Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Corpus Striatum; Dopamine Antagonist | 2016 |
Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Cross-Over Studies; Dru | 2008 |
The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Injections, I | 2008 |
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dose-R | 2009 |
A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents.
Topics: Adolescent; Adolescent Behavior; Antipsychotic Agents; Dibenzothiazepines; Female; Humans; Hyperprol | 2010 |
Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method | 2010 |
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
Topics: Antipsychotic Agents; Connecticut; Delayed-Action Preparations; Drug Substitution; Female; Fluphenaz | 2012 |
Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Asian People; China; Dibenzothiazepines; Female; Huma | 2012 |
Bone loss associated with hyperprolactinemia in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Bone Density; Bone Resorption; Cross-Sectional Studies; Estradiol; Fema | 2013 |
Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Estrogens; Female; | 2003 |
Risperidone-associated hyperprolactinemia: evaluation in twenty psychiatric outpatients.
Topics: Adult; Amenorrhea; Drug Administration Schedule; Female; Hospitals, Psychiatric; Humans; Hyperprolac | 2003 |
Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Hyperprolactinemia; M | 2005 |
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies | 2004 |
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Ind | 2005 |
Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; | 2005 |
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cognition Disorders; Dibenzothiazepines; Disord | 2006 |
A crossover study of prolactin changes associated with risperidone and olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Female; Humans; Hyperprolactinemia | 2006 |
Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy.
Topics: Antipsychotic Agents; Anxiety; Autistic Disorder; Behavior Therapy; Child Behavior Disorders; Child, | 2006 |
Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anxiety; Benzodiazepines; D | 2006 |
Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection.
Topics: Administration, Oral; Antipsychotic Agents; Humans; Hyperprolactinemia; Injections, Intramuscular; R | 2007 |
Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dopamine Antagonists; Humans; Hyperprolactinemia; Mal | 2007 |
Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Dysmenor | 2007 |
Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibe | 2007 |
A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Bromocriptine; Drug Therapy, Combination; Drugs, Chinese He | 2008 |
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
Topics: Adolescent; Adult; Amenorrhea; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female | 2002 |
95 other studies available for risperidone and Hyperprolactinemia
| Article | Year |
|---|---|
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolac | 2007 |
Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition; Dopamine; Drug Design; Humans; Hyperprol | 2021 |
Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Erectile Dysfunctio | 2023 |
Editorial: A Better Perspective on Antipsychotic-Related Hyperprolactinemia in Children and Adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Dopamine; Female; Humans; Hyperprolactinemia; | 2023 |
Therapeutic outcomes wide association scan of different antipsychotics in patients with schizophrenia: Randomized clinical trials and multi-ancestry validation.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Lipids; Olanzapine; Randomized Contr | 2023 |
Prolactin response to antipsychotics: An inpatient study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Humans; Hyperprolactinemia; | 2020 |
Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride.
Topics: Amisulpride; Antipsychotic Agents; Humans; Hyperprolactinemia; Prolactin; Risperidone; Schizophrenia | 2022 |
A Prepubertal Girl with Delusions of Pregnancy.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Delusions; Female; Humans; Hyperprolactinemia; | 2021 |
Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels.
Topics: Antipsychotic Agents; Aripiprazole; Female; Genetic Diseases, Inborn; Humans; Hyperprolactinemia; La | 2021 |
The central mechanism of risperidone-induced hyperprolactinemia.
Topics: Animals; Antipsychotic Agents; Arcuate Nucleus of Hypothalamus; Disease Models, Animal; Female; Hype | 2017 |
Hyperprolactinemia with low dose of risperidone in a young female.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; R | 2017 |
Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions.
Topics: Animals; Antipsychotic Agents; Apoptosis; Breast; Breast Neoplasms; Cell Differentiation; Female; Hu | 2018 |
UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder.
Topics: Age Factors; Autism Spectrum Disorder; Child; Female; Genetic Predisposition to Disease; Glucuronosy | 2018 |
Treatment of Risperidone-Associated Hyperprolactinemia With Aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Risperidone | 2018 |
Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
Topics: Adolescent; Antipsychotic Agents; Brief Psychiatric Rating Scale; Female; Hospitalization; Humans; H | 2019 |
Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients.
Topics: Adolescent; Alleles; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Cytochrome P-450 C | 2019 |
Increased prolactin concentrations in a patient with bipolar disorder.
Topics: Bipolar Disorder; Female; Humans; Hyperprolactinemia; Middle Aged; Prolactin; Risperidone | 2013 |
Granulomatous skin lesions on an amputated limb: a typical case of an immunocompromised district.
Topics: Amputation Stumps; Antipsychotic Agents; Granuloma; Humans; Hyperprolactinemia; Male; Risperidone; S | 2014 |
Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cabergoline; Diagnostic and Statistical Manual of Mental D | 2013 |
The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
Topics: Adolescent; Alleles; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Chil | 2013 |
Pathological bone mineral density in patients on long-term risperidone.
Topics: Antipsychotic Agents; Bone Resorption; Female; Humans; Hyperprolactinemia; Male; Risperidone; Schizo | 2014 |
Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Child; Family Health; Female; Humans; Hyperprolactinemia; Male; Pr | 2015 |
Using aripiprazole to treat new-onset hyperprolactinemia-related delusion of pregnancy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Female; Humans; Hyperprolactinemia; Risperidon | 2015 |
Prolactin monitoring in the acute psychiatry setting.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Male; Mental Diso | 2016 |
Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects.
Topics: Adolescent; Alleles; Antipsychotic Agents; Child; Cross-Sectional Studies; Female; Genetic Predispos | 2015 |
9-Hydroxyrisperidone-Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder.
Topics: Adolescent; Autism Spectrum Disorder; Child; Child, Preschool; Cohort Studies; Dose-Response Relatio | 2016 |
Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Estradiol; Female; | 2016 |
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapi | 2015 |
Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: A preliminary study.
Topics: Adult; Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Male; Mental Disorders; Middle Aged | 2016 |
Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Drug Resistance; Female; Genotype; Humans; Hyperprolactinemia; Male; Mi | 2016 |
Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Case-Control Studies; China; Cloza | 2016 |
Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Estradiol; Gonadotropins, Pituitary; Hormones; Humans; | 2009 |
Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Diagnosis, Differential; Female; Humans; Hyper | 2009 |
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Child; Child Behavior Disorders; Female; Gene Frequency; Genetic P | 2009 |
[Hyperprolactinemia in a child diagnosed with Asperger syndrome and hyperkinetic disorder treated with risperidone].
Topics: Antipsychotic Agents; Asperger Syndrome; Attention Deficit Disorder with Hyperactivity; Child, Presc | 2009 |
Aripiprazole treatment of risperidone-induced hyperprolactinemia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Piperazines; Prospective Studies; Qu | 2009 |
Attenuation of risperidone-induced hyperprolactinemia with the addition of aripiprazole.
Topics: Aripiprazole; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Quinolones; Receptors, Dop | 2009 |
Hyperprolactinemia in an adolescent with psychotic disorder on risperidone.
Topics: Adolescent; Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Psychotic Disorders; Risperido | 2009 |
Effects of lactational exposure of olanzapine and risperidone on hematology and lymphoid organs histopathology: a comparative study in mice neonates.
Topics: Animals; Animals, Newborn; Benzodiazepines; Female; Hematologic Diseases; Hyperprolactinemia; Lactat | 2010 |
Hyperprolactinaemia - a risperidone side-effect.
Topics: Affective Disorders, Psychotic; Antipsychotic Agents; Depressive Disorder, Major; Dose-Response Rela | 2010 |
Amenorrhoea - consequence of combined treatment with sulpiride and risperidone in a patient suffering from schizophrenia.
Topics: Amenorrhea; Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Mid | 2010 |
A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.
Topics: Absorptiometry, Photon; Adolescent; Anthropometry; Antipsychotic Agents; Body Mass Index; Bone Densi | 2010 |
Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Carbon Radioisotopes; Cerebellar Cortex; Cerebral Cort | 2010 |
Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Circadian Rhythm; Drug Administration Schedule; Drug M | 2010 |
Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzamides; Drug Synergism; Drug Therap | 2010 |
Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.
Topics: Adult; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; Middle Ag | 2010 |
Risperidone-induced bulbar palsy-like syndrome.
Topics: Antipsychotic Agents; Deglutition Disorders; Humans; Hyperprolactinemia; Male; Middle Aged; Risperid | 2011 |
Management of a patient with schizophrenia and underlying pituitary macroadenoma.
Topics: Adenoma; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bromocriptine; Dopamine Antagon | 2010 |
Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection.
Topics: Adult; Aripiprazole; Delayed-Action Preparations; Drug Therapy, Combination; Female; Follow-Up Studi | 2011 |
The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients.
Topics: Adult; Aged; Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Prolactin; | 2011 |
Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia.
Topics: Adult; Alcohol-Related Disorders; Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Female; Hu | 2012 |
Adjunctive treatment with low-dosage pramipexole for risperidone-associated hyperprolactinemia and sexual dysfunction in a male patient with schizophrenia.
Topics: Adult; Benzothiazoles; Drug Therapy, Combination; Erectile Dysfunction; Humans; Hyperprolactinemia; | 2011 |
Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia".
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fem | 2011 |
Granulomatous cutaneous lesions associated with risperidone-induced hyperprolactinemia in an amputated upper limb.
Topics: Amputation Stumps; Antipsychotic Agents; Aripiprazole; Forearm; Granuloma; Humans; Hyperprolactinemi | 2012 |
Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Clozapine; Female; Gluco | 2011 |
Idiopathic granulomatous mastitis associated with risperidone-induced hyperprolactinemia.
Topics: Adult; Antipsychotic Agents; Biopsy; Clozapine; Drug Substitution; Female; Granulomatous Mastitis; H | 2012 |
Hyperprolactinaemia on depot risperidone treated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Monitoring; Drug Substi | 2012 |
The challenges of clinical psychopharmacological management.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Community Mental Health Services; Comorbidity; Coopera | 2012 |
Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
Topics: Adult; Age Factors; Antipsychotic Agents; Biomarkers; Drug Substitution; Female; Humans; Hyperprolac | 2013 |
Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; | 2012 |
Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Estradiol; Female; Humans; Hyperprolactinem | 2002 |
Re: Prolactin levels and adverse events in patients treated with risperidone.
Topics: Antipsychotic Agents; Humans; Hyperprolactinemia; Prolactin; Risperidone; Schizophrenia | 2002 |
Risperidone-induced hyperprolactinemia in an elderly woman.
Topics: Aged; Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Mastitis; Risperidone; Schizophrenia | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Adult; Antipsychotic Agents; Autistic Disorder; Humans; Hyperprolactinemia; Hypogonadism | 2002 |
Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.
Topics: Adolescent; Adult; Antipsychotic Agents; Citalopram; Dibenzothiazepines; Drug Therapy, Combination; | 2002 |
Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine.
Topics: Adult; Comorbidity; Dibenzothiazepines; Female; Humans; Hyperprolactinemia; Quetiapine Fumarate; Ris | 2003 |
Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Estrogens | 2003 |
Risperidone-associated ejaculatory and urinary dysfunction in male adolescents.
Topics: Adolescent; Antipsychotic Agents; Ejaculation; Humans; Hyperprolactinemia; Male; Risperidone; Schizo | 2003 |
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzothiaze | 2003 |
Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication.
Topics: Adult; Antipsychotic Agents; Bone Density; Female; Humans; Hyperprolactinemia; Hypogonadism; Male; O | 2003 |
Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.
Topics: Adult; Antipsychotic Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergol | 2004 |
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2004 |
Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Clozapine; Dop | 2004 |
Prolactin elevation with ziprasidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Comorbidity; Depression, Post | 2004 |
Cardiopulmonary complications of ergot-derivative dopamine agonists.
Topics: Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Dru | 2004 |
Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Ejaculation; Female; Humans; Hyperprolactinemia; Male; | 2004 |
Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Sched | 2005 |
Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Clozapine; Cross-Sectional Studies; F | 2005 |
Reversal of symptomatic hyperprolactinemia by aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Drug Therapy, Combination; Female | 2005 |
Elevated prolactin levels in male youths treated with risperidone and quetiapine.
Topics: Adolescent; Antipsychotic Agents; Child; Cross-Sectional Studies; Dibenzothiazepines; Drug Therapy, | 2005 |
Risperidone-induced symptomatic hyperprolactinaemia in adolescents.
Topics: Adolescent; Antipsychotic Agents; Drug Monitoring; Female; Galactorrhea; Gynecomastia; Humans; Hyper | 2006 |
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Amenorrhea; Antipsychotic Agents; Aripiprazole; | 2006 |
Risperidone-induced hyperprolactinemia in adolescents: A case series.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Depressive Disorder, Major; Diagnostic and Statistica | 2006 |
Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Hyperprolactinemia; Obesit | 2006 |
Radioiodine uptake in non-lactating mammary glands: evidence for a causative role of hyperprolactinemia.
Topics: Breast; Carcinoma, Papillary; Female; Humans; Hyperprolactinemia; Iodine Radioisotopes; Kidney Failu | 2007 |
Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Child; Citalopram; Drug Ut | 2008 |
Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Bipolar Disorder; Cohort Studies; Cross-Sectional Studies; | 2007 |
Risperidone-induced prolactin elevations in premenopausal women with schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Isoxazoles; Piperidines; Premenopause; Pro | 1995 |
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Benzodiazepines; Female; Galactorrhea; Humans; Hyperprolact | 1998 |
Hyperprolactinemia and male sexual dysfunction.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Hyperprolactinemia; Male; Olanzapine; Pirenzep | 1999 |
[Galactorrhea and secondary amenorrhea in hyperprolactinemia].
Topics: Adult; Amenorrhea; Antipsychotic Agents; Diagnosis, Differential; Female; Galactorrhea; Humans; Hype | 2000 |
Characterization of inhibition by risperidone of the inwardly rectifying K(+) current in pituitary GH(3) cells.
Topics: Action Potentials; Animals; Antipsychotic Agents; Calcium Channels; Haloperidol; Hyperprolactinemia; | 2000 |
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
Topics: Adult; Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Human | 2000 |
Risperidone added to clozapine: impact on serum prolactin levels.
Topics: Adult; Age of Onset; Ambulatory Care; Antipsychotic Agents; Chronic Disease; Clozapine; Cross-Sectio | 2001 |
Prolactin levels in young children with pervasive developmental disorders during risperidone treatment.
Topics: Age Factors; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2001 |